MENU
Logo Made in Germany BIO 2018

MorphoSys Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-Term Skin Clearance In Patients With Moderate-To-Severe Plaque Psoriasis

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen) reported data from the Phase 3 VOYAGE 2 study of TREMFYA(R) (guselkumab), which demonstrated long-term skin clearance in patients with moderate to severe plaque psoriasis.

TREMFYA(R) is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL technology.

www.morphosys.com/media-investors/media-center/morph...

Exhibitor: Morphosys AG

Your personal organizer

Your personal organizer

Print list  |  Save as PDF
This is your personal organizer to manage your contacts to the German exhibitors.